GenewelThe Ministry of Food and Drug Safety approved the pain-reducing drug delivery kit ‘Welpass’, a pain-reducing drug delivery kit with safety and convenience

Genewel held a press conference on March 18 and announced plans to launch ‘Welpass’, a pain-reducing drug delivery kit with safety and convenience.
‘Welpass’ acquired a domestic patent in January last year in recognition of its excellence in technology. In April of this year, it obtained a manufacturing license from the Ministry of Food and Drug Safety and is preparing to apply for insurance registration. Currently, it has applied for patents in nine foreign countries including Europe and the United State.
This product is a new concept medical device that mixes a small amount of local anesthetic with a gel and applies it directly to the surgical incision to relieve pain and allow the drug to be released slowly for 72 hours.
By reducing the use of local anesthetics compared to existing products, the burden of side effects is reduced and convenience is enhanced. Although the content of local anesthetic of ‘Welpass’ is about 8 times lower than that of existing products, it has been confirmed through clinical trials that there is no difference in the pain control effect.
Existing products had the inconvenience of having to administer drugs through a separate pain control device, but the ‘Welpass’ also improved the convenience of use so that the procedure can be performed only by mixing and applying the product directly.